Pyodermia gangraenosum and portal vein thrombosis in a 33-year-old woman;Pyoderma gangraenosum und pfortaderthrombose bei einer 33jahrigen patientin

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 6, 1999, Pages 142-145

  Schiefke, I ^a   Halm, U ^a   Paasch, U ^a   Ponisch W ^a   Berr, F ^a   Mossner J ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; AZATHIOPRINE; C REACTIVE PROTEIN; HYDROXYUREA; PREDNISOLONE; THROMBIN; THROMBOPLASTIN;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTOSIS; PHYSICAL EXAMINATION; PORTAL VEIN THROMBOSIS; PROGNOSIS; PYODERMA GANGRENOSUM; RASH; SKIN ULCER; SPLENOMEGALY;

EID: 0033548134     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024255     Document Type: Article

References (10)

1. Anderson, J. E., F. R. Appelbaum, L. D. Fisher, G. Schoch, H. Shulman, C. Anasetti, W. I. Bensinger, E. Bryant, C. D. Buckner, K. Doney: Allogenic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82 (1993), 677-681.
2. Beran, M., H. Kantarjian, S. O'Brien, C. Koller, M. al-Bitar, S. Arbuck, S. Pierce, M. Moore, I. L. Abruzzese, M. Andreeff, M. Keating, E. Estey: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88 (1996), 2473-2479.
3. Bennett, J. M., D. Catovsky, M. T. Daniel, D. A. G. Galton, H. R. Gralnick, C. Sultan: French-American-British (FAB) cooperative group. Proposals for the classification of myelo-dysplastic syndromes. Brit. J. Haematol. 48 (1982), 189-199.
4. Cambier, N., E. Wattel, M. L. Menot, A. Guerci, C. Chomienne, P. Fenaux: All-trans retinoic acid in adult chronic myelomonocytic leukemia Results of a pilot study. Leukemia 10 (1996), 1164-1167.
5. Catalano, L., S. Improta, M. de Laurentiis, S. Molica, I. Majolino, P. Musto, A. Fragasso, S. de Placido, B. Rotoli: Prognosis of chronic myelomonocytic leukemia. Haematologica 81 (1996), 324-329.
6. Lee, G. R., T. C. Bithell, J. Foerster, J. W. Athens, J. N. Lukens: Acquired disorders associated with hematologic malignancies. In Wintrobe's Clinical Hematology, 9th Ed. 2(Lea & Febiger: Philadelphia, London 1993), 1949-1968.
7. Mellibovsky, L., A. Diez, J. Aubia, X. Nogues, E. Perez-Vila, S. Serrano, R. R. Recker: Long-standing remission after 25-OH D3 treatment in a case of chronic myelomonocytic leukemia. Brit. J. Haematol. 85 (1993), 811-812.
8. Morel, P., C. Declercq, M. Hebbar, F. Bauters, P. Fenaux: Prognostic factors in myelodysplastic syndromes, Critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques, Brit. J. Haematol. 94 (1996), 116-119.
9. Sanz, G. F., M. A. Sanz: Prognostic factors in myelodysplastic syndromes. Leuk. Res. 16 (1992), 77.
10. Wattel, E., A. Guerci, B. Hecquet, T. Economopoulos, A. Copple-Stone, B. Mahe, M. E. Couteaux, L. Resegotti, V. Voglova, C. Foussard, B. Pegourie, J. L. Michaux, E. Deconinck, A. M. Stoppa, G. Mufti, D. Oscier, P. Fenaux: A randomized trial of hydroxyureaversus VP16 in adult chronic myelomonocytic leukemia. Blood 88 (1996), 2480-2487.